Lacosamide Teva

Lacosamide, the active ingredient in Lacosamide Teva, is a sodium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset seizures, either as adjunctive therapy or as monotherapy in patients with focal onset epilepsy.

GNH USA supplies Lacosamide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across the European Union and other regulated markets. The company adheres to stringent quality standards and provides comprehensive regulatory support for importers.

Lacosamide is an antiepileptic drug that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures (adjunctive therapy): reduces seizure frequency when added to existing antiepileptic regimens. - Focal onset seizures (monotherapy): provides seizure control as the sole antiepileptic agent.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach often accompanied by the urge to vomit.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Rhabdomyolysis: muscle breakdown with elevated creatine kinase levels.

When prescribing Lacosamide, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: dose may need adjustment and renal function should be monitored. - Hepatic impairment: use with caution; monitor liver enzymes regularly. - Cardiac conduction